Limitations of Immunotherapy in Cancer

Area of Science:

• Oncology
• Immunology
• Biomedical Research

Background:

• Cancer remains a leading global cause of death despite medical progress.
• Immunotherapy has emerged as a powerful treatment modality for various malignancies.
• Recent advancements in immunotherapeutics show promise in improving patient outcomes and reducing tumor burden.

Purpose of the Study:

• To review the challenges and limitations of current cancer immunotherapy strategies.
• To examine the top five difficulties, setbacks, and drawbacks associated with immunotherapy.
• To discuss the therapy for middle-stage malignant growth in the context of immunotherapy.

Main Methods:

• Literature review of current advancements in cancer immunotherapy.
• Analysis of clinical response anomalies in targeted inhibition, CAR T-cell therapy, oncolytic viruses, and cytokines.
• Examination of challenges including prediction of efficacy, biomarker identification, anti-immunotherapy immunity, clinical assessment, and cost.

Main Results:

• Cancer cells employ diverse mechanisms to evade immunosurveillance, hindering treatment efficacy.
• Significant barriers include predicting patient response, identifying biomarkers, developing anti-immunotherapy immunity, and outdated clinical assessment plans.
• High treatment costs also pose a substantial challenge to widespread immunotherapy adoption.

Conclusions:

• Despite its potential, cancer immunotherapy faces significant hurdles that limit its clinical success.
• Addressing tumor evasion, improving response prediction, and optimizing clinical assessments are crucial for advancing immunotherapy.
• Further research and development are necessary to overcome these challenges and enhance the effectiveness of cancer immunotherapy.